Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors-Reference-Cited by-同舟云学术

Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors

Published:2021-09-24 Issue:1 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Abu‐Arja Mohammad H.¹²^ORCID,Osorio Diana S.²^ORCID,Lassaletta Alvaro³^ORCID,Graham Richard T.²⁴,Coven Scott L.²⁵,Stanek Joseph R.²,Bouffet Eric⁶^ORCID,Finlay Jonathan L.²^ORCID,Abdelbaki Mohamed S.²⁷^ORCID

Affiliation:

1. Division of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital Baylor College of Medicine Houston Texas

2. The Division of Hematology, Oncology and BMT, The Department of Pediatrics Nationwide Children's Hospital, The Ohio State University Columbus Ohio

3. The Department of Pediatric Oncology Hospital Universitario Niño Jesús Madrid Spain

4. The Department of Pediatrics Cincinnati Children's Hospital Medical Center Cincinnati Ohio

5. The Division of Pediatric Hematology‐Oncology Riley Hospital for Children and Indiana University School of Medicine Indianapolis Indiana

6. The Division of Hematology, Oncology The Hospital for Sick Children Toronto ON Canada

7. The Division of Hematology and Oncology, St. Louis Children's Hospital Washington University School of Medicine in St. Louis St. Louis Missouri

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29365

Reference21 articles.

1. Critical review of the management of primary central nervous nongerminomatous germ cell tumors

2. Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy

3. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013;Ostrom QT;Neuro‐Oncology,2016

4. Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors;Neuro-Oncology Practice;2023-10-14

2. Role of Alpha-Fetoprotein (AFP) in Diagnosing Childhood Cancers and Genetic-Related Chronic Diseases;Cancers;2023-08-28

3. Histogenesis of intracranial germ cell tumors: primordial germ cell vs. embryonic stem cell;Child's Nervous System;2023-01-03